Medicare Part D provides coverage for Entresto. Learn more about Medicare drug coverage and the costs of Entresto.

A new study from the PARADIGM-HF and PARAGON-HF clinical trials found that sacubitril/valsartan significantly reduced the ...

The USFDA has also approved Biocon Limited subsidiary's ANDA for Daptomycin for Injection (500mg Vial) for skin infections.

Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company ...

Biocon has received approval for its generic drug to treat chronic heart failure. The medicine can be used both for adults ...

Biocon's subsidiary, Biocon Pharma, has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Sacubitril/Valsartan tablets. This medication addresses ...

Sacubitril/valsartan or Sac/Val was launched in the US in July 2015, under brand name Entresto and in five European markets ...

Highlighted text has been updated as of August 30, 2024. The PARAGON-HF trial failed to show that sacubitril/valsartan reduced adverse events among patients with HFpEF. Patients with HFpEF were ...